AML in the Molecular Age: From Biology to Clinical Management
We appreciate your willingness to contribute an article to the upcoming Special Issue of the Journal of Clinical Medicine, which will focus on “AML in the Molecular Age: From Biology to Clinical Management”. In this Special Issue, we aim to discuss important scientific and clinical ongoing activitie...
Saved in:
| Main Authors: | , |
|---|---|
| 格式: | Online |
| 語言: | 英语 |
| 出版: |
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| 主題: | |
| 在線閱讀: | 29112 |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|
| _version_ | 1869529189232672768 |
|---|---|
| author | Celalettin Ustun (Ed.) Lucy A. Godley (Ed.) |
| author_browse | Celalettin Ustun (Ed.) Lucy A. Godley (Ed.) |
| author_facet | Celalettin Ustun (Ed.) Lucy A. Godley (Ed.) |
| author_sort | Celalettin Ustun (Ed.) |
| collection | Directory of Open Access Books |
| description | We appreciate your willingness to contribute an article to the upcoming Special Issue of the Journal of Clinical Medicine, which will focus on “AML in the Molecular Age: From Biology to Clinical Management”. In this Special Issue, we aim to discuss important scientific and clinical ongoing activities in AML. Scientific subjects will include articles concerning the molecular abnormalities, epigenetic mechanisms of disease/therapy as well as the role of the immune system in AML. Very interesting and uncommon subjects will include discussions of extramedullary disease and evaluations of the central nervous system by various imaging techniques. Experts will describe the role of hypomethylating agents in the management of AML and currently emerging and promising investigational therapies. Specifics of treament of pediatric and younger patients with AML. Clinical success relies greatly on supportive therapy, and we will discuss supportive therapy, including infection prophylaxis. Allogeneic hematopoietic stem cell transplantation remains the most effective measure for curing aggressive AML, and a variety of topics will be considered: donor selection, age of recipient, which has been increasing seemingly without limit; therefore, recipient/donor assessments are more important than ever in the aging population. Alternative donor use (e.g., cord blood and haploidentical individuals) has been increasing dramatically; when and who should be considered, what is being investigated? With significant changes occurring with respect to both donors and recipients, the pros and cons of using of anti-thymocyte globulin use in conditioning regimens will be also described. |
| format | Online |
| id | doab-20.500.12854ir-40768 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-407682024-03-31T13:10:06Z AML in the Molecular Age: From Biology to Clinical Management Celalettin Ustun (Ed.) Lucy A. Godley (Ed.) R5-920 RM1-950 hypomethylating agents molecular abberations T cell depletion umbilical cord blood transplantation adelosant and pediatric patients with AML novel therapy epigenetics allogeneic hematopoietic cell transplantation thema EDItEUR::M Medicine and Nursing We appreciate your willingness to contribute an article to the upcoming Special Issue of the Journal of Clinical Medicine, which will focus on “AML in the Molecular Age: From Biology to Clinical Management”. In this Special Issue, we aim to discuss important scientific and clinical ongoing activities in AML. Scientific subjects will include articles concerning the molecular abnormalities, epigenetic mechanisms of disease/therapy as well as the role of the immune system in AML. Very interesting and uncommon subjects will include discussions of extramedullary disease and evaluations of the central nervous system by various imaging techniques. Experts will describe the role of hypomethylating agents in the management of AML and currently emerging and promising investigational therapies. Specifics of treament of pediatric and younger patients with AML. Clinical success relies greatly on supportive therapy, and we will discuss supportive therapy, including infection prophylaxis. Allogeneic hematopoietic stem cell transplantation remains the most effective measure for curing aggressive AML, and a variety of topics will be considered: donor selection, age of recipient, which has been increasing seemingly without limit; therefore, recipient/donor assessments are more important than ever in the aging population. Alternative donor use (e.g., cord blood and haploidentical individuals) has been increasing dramatically; when and who should be considered, what is being investigated? With significant changes occurring with respect to both donors and recipients, the pros and cons of using of anti-thymocyte globulin use in conditioning regimens will be also described. 2021-02-11T08:08:49Z 2021-02-11T08:08:49Z 2018-10-12 12:12:38 2018 book 29112 9783038972815 9783038972808 https://directory.doabooks.org/handle/20.500.12854/40768 eng image/jpeg Attribution-NonCommercial-NoDerivatives 4.0 International https://play.google.com/books/publish/a/14935057684283403269#details/ISBN:9783038972808 https://www.mdpi.com/books/pdfview/book/778 https://www.mdpi.com/books/pdfview/book/778 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-03897-281-5 10.3390/books978-3-03897-281-5 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783038972815 9783038972808 208 open access |
| spellingShingle | R5-920 RM1-950 hypomethylating agents molecular abberations T cell depletion umbilical cord blood transplantation adelosant and pediatric patients with AML novel therapy epigenetics allogeneic hematopoietic cell transplantation thema EDItEUR::M Medicine and Nursing Celalettin Ustun (Ed.) Lucy A. Godley (Ed.) AML in the Molecular Age: From Biology to Clinical Management |
| title | AML in the Molecular Age: From Biology to Clinical Management |
| title_full | AML in the Molecular Age: From Biology to Clinical Management |
| title_fullStr | AML in the Molecular Age: From Biology to Clinical Management |
| title_full_unstemmed | AML in the Molecular Age: From Biology to Clinical Management |
| title_short | AML in the Molecular Age: From Biology to Clinical Management |
| title_sort | aml in the molecular age from biology to clinical management |
| topic | R5-920 RM1-950 hypomethylating agents molecular abberations T cell depletion umbilical cord blood transplantation adelosant and pediatric patients with AML novel therapy epigenetics allogeneic hematopoietic cell transplantation thema EDItEUR::M Medicine and Nursing |
| topic_facet | R5-920 RM1-950 hypomethylating agents molecular abberations T cell depletion umbilical cord blood transplantation adelosant and pediatric patients with AML novel therapy epigenetics allogeneic hematopoietic cell transplantation thema EDItEUR::M Medicine and Nursing |
| url | 29112 |
| work_keys_str_mv | AT celalettinustuned amlinthemolecularagefrombiologytoclinicalmanagement AT lucyagodleyed amlinthemolecularagefrombiologytoclinicalmanagement |